Exploring the Potential of Metallodrugs As Chemotherapeutics for Triple Negative Breast Cancer

Overview

Journal Chemistry

Specialty Chemistry

Date 2021 Apr 15

PMID 33857345

Citations 19

Authors

Nazia Nayeem

Maria Contel

Affiliations

Soon will be listed here.

Abstract

This review focuses on studies of coordination and organometallic compounds as potential chemotherapeutics against triple negative breast cancer (TNBC) which has one of the poorest prognoses and worst survival rates from all breast cancer types. At present, chemotherapy is still the standard of care for TNBC since only one type of targeted therapy has been recently developed. References for metal-based compounds studied in TNBC cell lines will be listed, and those of metal-specific reviews, but a detailed overview will also be provided on compounds studied in vivo (mostly in mice models) and those compounds for which some preliminary mechanistic data was obtained (in TNBC cell lines and tumors) and/or for which bioactive ligands have been used. The main goal of this review is to highlight the most promising metal-based compounds with potential as chemotherapeutic agents in TNBC.

Citing Articles

Synthesis and Evaluation of Cytotoxic Activity of RuCp(II) Complexes Bearing (Iso)nicotinic Acid Based Ligands.

Marques B, Engracia D, Machado J, Coelho J, Mendes F, Morais T Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861159 PMC: 11768749. DOI: 10.3390/ph18010097.

Unpredictable Dynamic Behaviour of Ruthenium Chelate Pyrrole Derivatives.

Drius G, Tarroni R, Birchmeier M, Parolin C, Boga C, Monari M Molecules. 2024; 29(13).

PMID: 38999019 PMC: 11242957. DOI: 10.3390/molecules29133068.

Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound.

Nayeem N, Sauma S, Ahad A, Rameau R, Kebadze S, Bazett M ACS Pharmacol Transl Sci. 2024; 7(5):1364-1376.

PMID: 38751641 PMC: 11092013. DOI: 10.1021/acsptsci.4c00020.

PdSpermine as an Alternative Therapeutics for Cisplatin-Resistant Triple-Negative Breast Cancer.

Carneiro T, Batista de Carvalho A, Vojtek M, Laginha R, Marques M, Diniz C J Med Chem. 2024; 67(8):6839-6853.

PMID: 38590144 PMC: 11056979. DOI: 10.1021/acs.jmedchem.4c00435.

Metals in Cancer Research: Beyond Platinum Metallodrugs.

Casini A, Pothig A ACS Cent Sci. 2024; 10(2):242-250.

PMID: 38435529 PMC: 10906246. DOI: 10.1021/acscentsci.3c01340.

References

Scibior A, Pietrzyk L, Plewa Z, Skiba A . Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends. J Trace Elem Med Biol. 2020; 61:126508. PMC: 7152879. DOI: 10.1016/j.jtemb.2020.126508. View

Corte-Real L, Karas B, Bras A, Pilon A, Avecilla F, Marques F . Ruthenium-Cyclopentadienyl Bipyridine-Biotin Based Compounds: Synthesis and Biological Effect. Inorg Chem. 2019; 58(14):9135-9149. DOI: 10.1021/acs.inorgchem.9b00735. View

Zamora A, Perez S, Rothemund M, Rodriguez V, Schobert R, Janiak C . Exploring the Influence of the Aromaticity on the Anticancer and Antivascular Activities of Organoplatinum(II) Complexes. Chemistry. 2017; 23(23):5614-5625. DOI: 10.1002/chem.201700717. View

Matos C, Adiguzel Z, Yildizhan Y, Cevatemre B, Onder T, Cevik O . May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?. Eur J Med Chem. 2019; 176:492-512. DOI: 10.1016/j.ejmech.2019.04.070. View

Irace C, Misso G, Capuozzo A, Piccolo M, Riccardi C, Luchini A . Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action. Sci Rep. 2017; 7:45236. PMC: 5368645. DOI: 10.1038/srep45236. View

Oliveira K, Peterson E, Carroccia M, Cominetti M, Deflon V, Farrell N . Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer. Dalton Trans. 2020; 49(45):16193-16203. DOI: 10.1039/d0dt01091j. View

Biersack B, Ahmad A, Sarkar F, Schobert R . Coinage metal complexes against breast cancer. Curr Med Chem. 2012; 19(23):3949-56. DOI: 10.2174/092986712802002482. View

Cvek B, Milacic V, Taraba J, Dou Q . Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J Med Chem. 2008; 51(20):6256-8. PMC: 2574941. DOI: 10.1021/jm8007807. View

Alessio E, Messori L . NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. Molecules. 2019; 24(10). PMC: 6571951. DOI: 10.3390/molecules24101995. View

10.

Zhang S, Yuan H, Guo Y, Wang K, Wang X, Guo Z . Towards rational design of RAD51-targeting prodrugs: platinum-artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells. Chem Commun (Camb). 2018; 54(83):11717-11720. DOI: 10.1039/c8cc06576d. View

11.

Kowalski S, Wyrzykowski D, Inkielewicz-Stepniak I . Molecular and Cellular Mechanisms of Cytotoxic Activity of Vanadium Compounds against Cancer Cells. Molecules. 2020; 25(7). PMC: 7180481. DOI: 10.3390/molecules25071757. View

12.

Shen J, Kim H, Wolfram J, Mu C, Zhang W, Liu H . A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer. Nano Lett. 2017; 17(5):2913-2920. PMC: 5484597. DOI: 10.1021/acs.nanolett.7b00132. View

13.

Wang R, Chen H, Yan W, Zheng M, Zhang T, Zhang Y . Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships. Eur J Med Chem. 2020; 190:112109. DOI: 10.1016/j.ejmech.2020.112109. View

14.

Atmaca H, Ozkan A, Zora M . Novel ferrocenyl pyrazoles inhibit breast cancer cell viability via induction of apoptosis and inhibition of PI3K/Akt and ERK1/2 signaling. Chem Biol Interact. 2016; 263:28-35. DOI: 10.1016/j.cbi.2016.12.010. View

15.

Onodera T, Momose I, Kawada M . Potential Anticancer Activity of Auranofin. Chem Pharm Bull (Tokyo). 2019; 67(3):186-191. DOI: 10.1248/cpb.c18-00767. View

16.

Wedlock L, Kilburn M, Cliff J, Filgueira L, Saunders M, Berners-Price S . Visualising gold inside tumour cells following treatment with an antitumour gold(I) complex. Metallomics. 2011; 3(9):917-25. DOI: 10.1039/c1mt00053e. View

17.

Sava G, Capozzi I, Clerici K, Gagliardi G, Alessio E, Mestroni G . Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis. 1998; 16(4):371-9. DOI: 10.1023/a:1006521715400. View

18.

Ronconi L, Marzano C, Zanello P, Corsini M, Miolo G, Macca C . Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. J Med Chem. 2006; 49(5):1648-57. DOI: 10.1021/jm0509288. View

19.

Mbaba M, Mare J, Sterrenberg J, Kajewole D, Maharaj S, Edkins A . Novobiocin-ferrocene conjugates possessing anticancer and antiplasmodial activity independent of HSP90 inhibition. J Biol Inorg Chem. 2018; 24(2):139-149. DOI: 10.1007/s00775-018-1634-9. View

20.

Rada J, Forte J, Gontard G, Corce V, Salmain M, Rey N . Isoxazole-Derived Aroylhydrazones and Their Dinuclear Copper(II) Complexes Show Antiproliferative Activity on Breast Cancer Cells with a Potentially Alternative Mechanism Of Action. Chembiochem. 2020; 21(17):2474-2486. DOI: 10.1002/cbic.202000122. View